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Background. Disruption of the intestinal homeostasis and tolerance towards the resident microbiota is a major mechanism
involved in the development of inflammatory bowel disease. While some bacteria are inducers of disease, others, known as
probiotics, are able to reduce inflammation. Because dendritic cells (DCs) play a central role in regulating immune responses
and in inducing tolerance, we investigated their role in the anti-inflammatory potential of probiotic lactic acid bacteria.
Methodology/Principal Findings. Selected LAB strains, while efficiently taken up by DCs in vitro, induced a partial
maturation of the cells. Transfer of probiotic-treated DCs conferred protection against 2, 4, 6-trinitrobenzenesulfonic acid
(TNBS)-induced colitis. Protection was associated with a reduction of inflammatory scores and colonic expression of pro-
inflammatory genes, while a high local expression of the immunoregulatory enzyme indolamine 2, 3 dioxgenase (IDO) was
observed. The preventive effect of probiotic-pulsed DCs required not only MyD88-, TLR2- and NOD2-dependent signaling but
also the induction of CD4+ CD25+ regulatory cells in an IL-10-independent pathway. Conclusions/Significance. Altogether,
these results suggest that selected probiotics can stimulate DC regulatory functions by targeting specific pattern-recognition
receptors and pathways. The results not only emphasize the role of DCs in probiotic immune interactions, but indicate
a possible role in immune-intervention therapy for IBD.
Citation: Foligne B, Zoumpopoulou G, Dewulf J, Ben Younes A, Chareyre F, et al (2007) A Key Role of Dendritic Cells in Probiotic Functionality. PLoS
ONE 2(3): e313. doi:10.1371/journal.pone.0000313
INTRODUCTION
Dendritic cells (DCs) are antigen presenting cells (APC) that play
a central role in orchestrating immune responses to self and
foreign antigens. Contact with antigens or inflammatory stimuli,
can induce the maturation of DCs, accompanied by functional
and phenotypic changes. In their mature state, the DCs are
primed to activate T cells towards a Th1/Th2 polarization. In the
absence of inflammation, the DCs remain in an immature state,
leading to either the deletion of effector T cells or the generation of
regulatory T cells (Treg) [1]. Recent data highlight the critical role
of naturally occurring CD4+CD25+ Treg cells in the control of
normal immune homeostasis [2]. Little is known, however, about
the role of APC in the development and/or peripheral expansion
of Treg cells, nor about the mechanisms by which this occurs. It
remains an attractive notion that by controlling the maturation of
DCs, the outcome of an immune response can be modulated.
In order to mount an effective immune response in intestinal
mucosa, the immune system has to discriminate harmful antigens
on the one hand, and tolerate commensal bacterial and dietary
antigens in the intestinal environment on the other hand. The
failure to control these responses leads to a breakdown of tolerance
towards resident microbiota and has been proposed as one
mechanism involved in the development of inflammatory bowel
diseases (IBD) [3]. It has also been shown recently that recognition
of commensal bacteria by Toll like receptors (TLR) plays a crucial
role in maintaining homeostasis [4]. Two recent reports have
shown that the commensal flora could have an anti-inflammatory
effect through an inhibition of the nuclear transcription factor
NFkB, either by inhibition of IkB ubiquitination [5] or by
regulating nuclear export of the NFkB relA subunit [6].
Probiotic bacteria, mainly belonging to the lactic acid bacteria
(LAB) family, are well known to exert beneficial effects in human
or animal health. Regular intake of probiotic bacteria contributes
to immune homeostasis by altering microbial balance or by
interacting with the gut immune system, explaining their potential
effect in IBD. Consequently, therapeutic approaches designed to
modulate the local microenvironment using probiotics, have been
tested in animal models of colitis [7], as well as in human clinical
trials with patients suffering from IBD [8–10]. Although there is
a considerable body of information concerning the protective
efficacy of probiotics, little is known about the precise mechanisms
of action by which such bacteria may exert their beneficial effects.
Interactions with TLRs and DCs in the gut are believed to be
involved in this communication. It was recently reported that
lactobacilli can differentially modulate DC maturation [11,12].
Indeed, we and others have shown that probiotics may present
distinct strain-specific immunomodulatory capacities both in vitro
and in vivo. This strain-specific in vitro immunomodulation capacity
seems to be closely correlated with the in vivo anti-inflammatory
potential of the strain [13]. The anti-inflammatory effects of
lactobacilli observed both after oral or systemic administrations
[14,15] suggest that mechanisms, distant from the site of
inflammation could involve regulatory cell populations. Indeed,
a recent in vitro study demonstrated that lactobacilli, in a strain-
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specific manner, were able to prime DCs to promote the
development of Treg cells through DC-SIGN interaction [16].
Recent studies have shown that the conversion of DCs to
tolerogenic DCs could lead to the inhibition of NFkB [17] and
could be used therapeutically to prevent allograft rejection [18].
One of the mechanisms exploited by tolerogenic DCs involves
expression of indoleamine 2, 3 dioxygenase (IDO), a tryptophan-
catabolizing enzyme that can exert regulatory effects on T cells by
tryptophan depletion [19,20]. Local overexpression of IDO in IBD
patients has been suggested as an anti-inflammatory mechanism to
counterbalance the tissue-damaging effects of activated T cells
infiltrating the colonic mucosa [21]. To our knowledge, tolero-
genic DCs has never been used to protect against IBD. In
a contribution to unravel the mechanism by which probiotics may
exert their anti-inflammatory effects, we demonstrate in this paper
that interaction of DCs with selected probiotic bacteria can lead to
the induction of regulatory DCs able to protect mice from colitis
RESULTS
LAB are efficiently taken up by BMDCs
We examined whether and how BMDCs internalized lactobacilli
(L. rhamnosus Lr32 strain) by transmission electron microscopy.
While after 2 h incubation at 37uC, only a small proportion of the
bacteria was found inside the BMDCs (,10%) (data not shown), at
18 h most BDMCs (.80%) have internalized bacteria that show
various stages of degradation. The bacteria were always included
in vacuoles and phagosomes and never free in the cytosol (Fig. 1),
suggesting that L. rhamnosus was taken up by conventional
phagocytosis, as previously observed for Streptococcus gordonii with
human DCs [22]. The number of bacteria present in each BMDC
section ranged from 1 to 24 with an average of 7 bacteria per cell.
Lactic acid bacteria differentially activate dendritic
cells
We have previously observed that LAB have differential immuno-
modulatory effects on PBMC, with some strains (i.e. L. salivarius
Ls33, L. rhamnosus Lr32) having low in vitro pro-inflammatory and
high immuno-regulatory capacities and correlating well with an
efficient protective effect in murine colitis, and other strains (i.e. L.
acidophilus NCFM, L. lactis MG1363) exhibiting an opposite
immunological profile, and lacking a protective effect in vivo
(Table 1). To determine the role of DCs in the anti-inflammatory
capacity of these probiotic strains, we first evaluated the responses
of mouse BMDCs to these LAB, using E. coli TG1 as a pro-
inflammatory control strain. BMDCs were incubated with the
bacteria at a ratio of 10:1 in the presence of 150 mg/ml
gentamycin, condition that completely impair bacterial over-
growth. Cytokine and chemokine productions were evaluated in
the supernatant after 18–20 h culture (Fig. 2). The LAB strains
NCFM and MG1363 as well as E. coli stimulated BMDC to
produce large amounts of IL-6, TNF-a, MIP-1a and MIP-2 as well
as significant levels of IL-12 and IL-10. In contrast, both Ls33 and
Lr32 strains induced poor secretion of these cytokines and
chemokines. Therefore, like observed in human PBMC model,
LAB strains can be classified as pro-inflammatory and non-
inflammatory also in the mouse BMDC infection model.
Next, we examined the ability of the LAB strains to activate co-
stimulatory functions in BMDCs. Again a great difference was
observed among the LAB strains in their capacity to up-regulate
the expression of MHC class II and co-stimulatory molecules
(CD86, CD40) (Fig. 3). Lr32 and Ls33, previously selected for their
in vitro and in vivo anti-inflammatory properties, induced very low
expression levels of co-stimulation markers as compared to
untreated DCs, while strong and similar up-regulation was
observed for the LAB strains NCFM, MG1363 and E. coli.
Indeed, the two groups of LAB differ in their capacity to induce
the production of pro-inflammatory cytokines by BMDCs and the
surface expression of co-stimulatory signals. Subsets of DCs with
such immature phenotype, called regulatory or tolerogenic DCs,
are now recognized to induce and maintain peripheral tolerance.
All these observations suggest that LAB strains Lr32 and Ls33
could exert their in vivo anti-inflammatory effects through
induction of tolerogenic DCs.
Administration of probiotic-treated BMDCs protect
mice from colitis
To investigate the role of DCs in the anti-inflammatory capacity of
probiotic bacteria, we assessed whether the intraperitoneal
administration of LAB-treated BMDCs could rescue mice from
colitis induced by intra-rectal administration of TNBS. As
compared to the TNBS-control group, the administration of
untreated BMDCs did not rescue mice from colitis (p = 0.3116). In
contrast, intra-peritoneal administration of L. rhamnosus Lr32 or L.
salivarius Ls33-treated BMDCs, led to a considerable attenuation of
the colitis, with reduced weight loss, improved clinical parameters
(rectal bleeding, lethargy, and stool consistency; data not shown)
and a significant reduction (p = 0.0003 and p = 0.0033, respec-
Figure 1. Internalization of L. rhamnosus by BMDCs. BMDCs were
incubated for 18 h with Lr32 strain at a bacteria-to-DC ratio of 10 and
then processed for transmission electron microscopy. Bacteria are
visible within membrane-bound phagosomes at various stages of
degradation (arrows). Bar, 2 mm.
doi:10.1371/journal.pone.0000313.g001
Table 1. Immuno-modulatory and protective properties of
strains used in the study
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Species Strains IL-10/IL-12a protectionb Origine/Ref
L. salivarius Ls33 36.265.8 + commercial strain
L. rhamnosus Lr32 15.7565.07 + commercial strain
L. acidophilus NCFM 3.2260.73 2 commercial strain
L. lactis MG1363 0.7860.18 2 cheese starter [53]
E. coli TG1 31.8267.26 2 commensal strain [54]
aIL-10/IL-12 ratio was previously determined by the capacity of the strains to
induce IL-10 and IL-12 after in vitro PBMC stimulation and b protection
indicated the capacity of the strains to protect mice from TNBS-induced colitis
doi:10.1371/journal.pone.0000313.t001..
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Figure 2. Cytokine (A) and chemokine (B) response of murine BMDCs (0.56106 cells/ml) derived from BALB/c mice to stimulation with strains L.
rhamnosus Lr32, L. salivarius Ls33, L. acidophilus NCFM, L. lactis MG1363 and E. coli TG1. Bacteria were collected after overnight culture and the
stimulation of BMDC was done at a ratio of 10:1 (bacteria/DC). Results represent the mean6SEM of 7 independent experiments.
doi:10.1371/journal.pone.0000313.g002
Probiotic-Exposed DCs
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Figure 3. Phenotypic characteristics of non-treated (control) or bacteria-pulsed BMDCs from BALB/c mice. Plots show flow cytometric profiles of MHC
class II, CD86 and CD40 expression (thick line) in comparison to an isotypic control (thin line). The data are representative of 4 independent
experiments.
doi:10.1371/journal.pone.0000313.g003
Probiotic-Exposed DCs
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tively) of macroscopic inflammation scores (Fig. 4A and 4B).
Interestingly, the level of protection induced by probiotic-treated
BMDCs was the same as that obtained with a pre-treatment by
prednisone (at 10 mg/kg), a well known anti-inflammatory drug.
Consistent with these data, the histological score of inflammation
(Ameho score) was significantly reduced (p,0.01) in mice that
were pre-treated with Lr32-DC, in comparison to the TNBS
control group or the group of mice that received the non-treated
DCs (Fig. 5E). We found substantial histological disruption of the
villus and crypt structure concomitant with extensive cellular
infiltration in the colonic lamina propria of mice that have been
administered with TNBS alone (Fig. 5B) or with non-treated DCs
(Fig. 5C). As expected, colonic inflammation, induced by TNBS,
was totally abolished in mice that were transferred with Lr32-
treated DCs (Fig. 5D), resulting in almost similar pictures as
observed in healthy control mice (Fig. 5A). Additionally, the
degree of polymorphonuclear neutrophil infiltration, assessed by
quantifying myeloperoxidase (MPO) activity in colon extracts was
also significantly decreased (p,0.05) in mice that received the
Lr32-treated DCs in comparison to the TNBS control group
(Fig 6A). Similarly, a decrease of SAA was also obtained in the sera
of mice that had been treated with Lr32-pulsed DCs (Fig 6B). The
protective effect of Lr32-treated BMDCs was verified in three
additional experiments, leading to 59 to 74% protection (data not
shown). Moreover, we confirmed as previously published [15] that
intra-peritoneal administration of 108 CFU of Lr32 bacteria could
also significantly (p = 0.01) protect mice from colitis, where,
interestingly, the protection induced by Lr32-treated BMDCs
was found to be significantly (p = 0.0036) higher (Fig 3A). Finally,
we evaluated in two independent experiments, the effect of Lr32-
pulsed DCs in an acute DSS-induced model of colitis (7 days of
daily consumption of drinking water containing 6% DSS). This
caused loose and bloody stools (9/9 mice), progressive weight loss
and significant shortening of the colon in control mice. However,
when mice were pre-treated with Lr32-pulsed DCs, we only
partially abolished the bloody stools (6/9), but we measured no
significant amelioration of weight loss, colon size or inflammation
parameters (MPO) (data not shown).
Figure 4. Protective effect of intra-peritoneal administration of LAB-
treated BMDCs on acute TNBS-induced colitis in BALB/c mice. Wallace
inflammation scores were calculated after a TNBS challenge in mice
either not treated (None) or intraperitoneally injected by untreated
BMDCs (DC) or BMDCs treated with (A) Lr32 (Lr32-DC) or (B) Ls33 (Ls33-
DC) strains. The comparison between the TNBS-control groups and the
groups that received the corresponding untreated BMDCs (DC) was
calculated using the Mann-Whitney U test (,0.01, **; p,0.001, ***).
Percentage mortality and protection (reduction of the mean Wallace
scores of mice treated with BMDCs, in relation to the mean score of
TNBS control group) are also indicated. In A, the effect of Lr32-treated
BMDCs was also compared to the intra-peritoneal administration of 108
CFU of Lr32 bacteria (Lr32-IP) and in B, an additional group of mice was
included, pre-treated with 3 intra-peritoneal administrations of
prednisone (10 mg/kg), representing a clinically relevant standard
treatment for Crohn’s disease (36). Data represent the mean6SEM of
two representative experiments (number of mice n= 10).
doi:10.1371/journal.pone.0000313.g004
Figure 5. Representative histology of May-Grunwald stained sections
(610) of the distal colon from healthy control mice (A), mice with acute
TNBS-induced colitis that have been or not (B) administered with non-
treated DC (C) and Lr32-treated DC (D) and corresponding Ameho
scores (E), mean6SEM (number of mice n = 10).
doi:10.1371/journal.pone.0000313.g005
Probiotic-Exposed DCs
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The protective effect of probiotic-treated BMDC is
associated with a down-regulation of pro-
inflammatory mediators
In order to analyze the mechanisms of protection of probiotic-
pulsed BMDCs in TNBS-induced colitis, the modulation of the
expression of selected genes was assessed in the animal colons by
real time PCR using the Taq-Man qRT-PCR technology. As
shown in Figure 7, the colitis, developed after TNBS administra-
tion, largely enhanced the expression of TNF-a, IL-6, IL-1b, IL-
12, IL-23, IL-17, Cox-2, IL-10, and IFNb genes, with a fold
increase in mRNA levels of 28.7, 89.26, 303.9, 36.03, 9.14,
329.00, 32.07, 10.89, and 24.16, respectively compared to healthy
mice. A dramatic increase of MIP-2 gene expression was also
observed showing a 37,626 fold increase compared to naı¨ve mice.
Interestingly, by comparing individually the Wallace inflammation
scores and the gene expression levels, an excellent correlation was
found using the Spearman rank test, (r values ranging from 0.75 to
0.84; data not shown). The administration of untreated BMDCs
had no significant impact on the global expression of pro-
inflammatory genes. However, we observed a slight upregulation
of IL-1b, IL-23 and COX-2 expression, while a downregulation of
IL-12 and IL-17 expression was detected. As expected, adminis-
tration of Lr32-treated BMDCs greatly reduced the expression of
all these genes. Surprisingly, IL-10 and IFNb expressions were also
up-regulated during colitis induction and were down-regulated
upon probiotic-pulsed DC treatment. In addition, the expression
of IFNc and IDO was not altered in the colon upon colitis
induction. In contrast, treatment of animals with Lr32-pulsed DCs
promoted an acute over-expression of IFNc and IDO (Fig 7).
Finally, FoxP3 colonic expression was not modulated in any group
of mice (data not shown).
Depletion of CD4+ CD25+ cells totally abrogated the
protective effect induced by probiotic-treated DC
Previous studies have shown that anti-CD25 monoclonal antibody
(mAb) was capable of depleting CD25+ Treg cells in vivo [23] with
a loss of CD4+ FOXP3+ cells as recently commented by Zelenay and
Demengeot [24] and by Stephens and Anderton [25]. To analyze
the involvement of the naturally occurring CD4+ CD25+ T cell
population in the protective effect of probiotic-treated BMDCs, we
investigated the effect of in vivo intra-peritoneal administration of an
anti-CD25 rat mAb in comparison to the effect of an isotype control
rat IgG. Depletion was confirmed 24 and 48 h after injection in
spleen and mesenteric lymph nodes, by flow cytometry using anti
FITC-labeled anti-CD4 and PE-labeled anti-CD25 mAbs (data not
shown). As shown in Figure 8, similar inflammatory scores were
obtained in TNBS, anti-CD25/TNBS- and isotype/TNBS-treated
groups, confirming that the injection of both mAbs had no significant
impact on the TNBS-induced colitis (p = 0.25 and 0.20, respectively).
As expected, Lr32-treated BMDCs significantly protected mice
against TNBS-induced colitis in untreated mice (p = 0.004) or in
mice injected with irrelevant rat IgG (p = 0.004). In contrast,
depletion of CD25+ cells totally abrogated the protective effect of
probiotic-treated BMDCs (p = 0.45). These experiments suggest that
probiotic treatment of DC promotes in vivo a protective effect
dependent on the CD4+ CD25+ Treg population.
PRR signaling is required for anti-inflammatory
effects of probiotic-treated BMDCs
To analyse the requirement of pattern recognition receptors (PRR)
signaling in the anti-inflammatory effects of probiotic-treated DCs,
BMDCs were derived from C57BL/6 or TLR22/2, MyD882/2
and NOD22/2 KO mice. We also analyzed the role of IL-10 by
using BMDCs derived from IL-102/2 mice. The defect in TLR2
and NOD2 in the respective KO mice used was confirmed using
specific ligands, Pam3Cys-Ser-(Lys)4 (Pam3C) and N-Acethylmur-
amyl-L-alanyl-D-iso-glutamine hydrate (MDP) respectively, using
lipopolysaccharide (LPS) as positive control (data not shown). The
capacity of LAB to activate BMDCs derived from C57/Bl6 (the
genetic background of deficient mice) was similar to results obtained
in BALB/c (Figure 1 and 2). No major differences were observed in
the activation of BMDCs derived from TLR2- and NOD2-deficient
mice. Stimulation of cells derived from the IL-102/2 mice, also had
no effect other than the expected absence of IL-10 production. In
contrast in MyD882/2 DCs, cytokine and chemokine production
was totally abolished and a partial reduction of co-stimulation was
observed, as previously reported [26] (data not shown).
We finally evaluated whether the administration of Lr32-treated
BMDCs derived from KO mice could protect C57BL/6 mice
from colitis. As C57BL/6 are more resistant to TNBS-induced
colitis [27], a higher dose of the hapten was used to obtain a similar
score of inflammation. Under these comparable conditions, Lr32-
treated BMDCs from C57BL/6 mice again induced a significant
protection when compared to the TNBS control group (p = 0.01)
and the group that received the untreated BMDCs (p = 0.03)
(Fig. 9). Similar results were obtained when using BMDCs derived
from the IL-102/2 mice, indicating that IL-10 was not involved in
the Lr32-mediated protection. In the same conditions, the protec-
tive effect of Lr32-treated DCs was completely abolished when
cells were derived from MyD882/2 , TLR22/2 and NOD22/2
mice (non-significant p-values of 0.42, 0.38, 0.11, respectively,
Figure 6. Colonic myeloperoxydase (MPO) activity (A) and Serum
Amyloid A protein levels obtained 48 h after TNBS-induced colitis. Mice
were left untreated (None) or IP administered with untreated BMDC
(DC) or Lr32-treated BMDCs (Lr32-DC). The values are expressed as the
mean6SEM (number of mice n = 10).
doi:10.1371/journal.pone.0000313.g006
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versus the TNBS, non-treated WT mice), suggesting that the anti-
inflammatory effects conferred by Lr32-treated DC required
signaling involving these molecules. We could therefore conclude
that the protective effect against colitis likely requires innate
detection of microbial products derived from specific LAB strains
by DCs, thereby leading to the development of tolerogenic DC
dependent on active cell signalling.
DISCUSSION
It is now well accepted that in genetically susceptible individuals,
intestinal microbes can contribute to the initiation and perpetu-
ation of chronic mucosal inflammation. Various factors are likely
involved in the loss of tolerance to the patient’s commensal flora in
IBD. Although many types of immune cells regulate immune
Figure 7. Quantitative real time PCR analysis of mRNA expression of pro-inflammatory or regulatory mediators in colons obtained 48 h after TNBS-
induced colitis. Mice were left untreated (None) or IP administered with untreated BMDC (DC) or Lr32-treated BMDCs (Lr32-DC). The values are
expressed as the mean ratio6SEM of mRNA levels after TNBS challenge compared with non challenged healthy mice.
doi:10.1371/journal.pone.0000313.g007
Probiotic-Exposed DCs
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responses, most attention has focused on regulatory T cells as a way
to cure or prevent colitis in mouse models of intestinal
inflammation [28]. Partially mature DCs possess inherent
tolerogenic properties, and it is an attractive notion that by
controlling or directing the maturation of DCs, T cell activation
can be biased towards the generation of Treg cells. This principle,
when managed properly, could proof to be extremely valuable in
correcting, in a controlled way, a large number of immune
disorders. Preventive properties of probiotic microorganisms
against colonic inflammation have been reported [8]. Neverthe-
less, the unraveling of the mechanism of action is mandatory to
allow the establishment of criteria for the selection of the most
efficient strains. Immunoregulatory effects of probiotic strains
seem to be strain-specific and linked to the composition of the cell
surface [29]. We and others previously showed that probiotics are
able to exert anti-inflammatory effects distant from the site of
administration, suggesting the involvement and migration of
regulatory cells [14,15]. Two recent studies reported that
probiotics can improve murine colitis by inducing TGF-b bearing
regulatory T cells [30] and can induce in vivo peripheral T cell
hypo-responsiveness [31], suggesting a modulation through DC
function. In the present study, we particularly addressed the role of
DCs in the protective effect mediated by probiotic strains. We
confirmed that LAB differentially interact with DCs. The strains L.
rhamnosus Lr32 and L. salivarius Ls33, while being taken up very
efficiently by DCs, were unable to trigger cytokine and chemokine
production as well as the expression of co-stimulatory molecules,
in contrast to other LAB strains investigated. We hypothesized
therefore that Lr32 and Ls33 induced the differentiation of DCs
into tolerogenic DCs. Indeed, the probiotic-pulsed DCs exhibiting
this tolerogenic phenotype, were able to protect mice against
TNBS-induced colitis, after intra-peritoneal administration. The
tolerogenic properties of DCs are not only associated with a failure
to mature since untreated immature DCs are unable to confer
protection. This protective effect by tolerogenic DC’s is probably
conveyed by an effect of T cells. According to previous studies,
immune mechanisms involved in the inflammatory processes are
different between DSS- and TNBS-induced colitis [32]. While
macrophages seem to be involved in the DSS model, T cells play
a pivotal role in the TNBS-mediated colitis. In this study, we could
not find any substantial effect of probiotic-pulsed DCs on DSS-
induced colitis, suggesting that the treatment does not regulate
macrophage functions in the pathogenesis of colitis. Similar
observations have been reported for several treatments that
protected in one model but not in the other [33,34]. TNBS colitis
is associated with a Th1-mediated immune response, which clearly
mimics human IBD. Therefore the enhancement of transcription
of pro-inflammatory cytokine genes has been reported in this
model [35]. We also observed that the expression of pro-
inflammatory mediators was strongly up-regulated in TNBS-
induced colitis while strongly reduced in mice treated with Lr32-
pulsed DCs. It was established that IL-23 plays a key role in IBD
by driving the development of IL-17 producing T cells that
promote the production of the main inflammatory mediators [36].
We could show increased mRNA expression levels of both IL-23
and IL-17 upon TNBS treatment, which were greatly reduced by
Lr32-pulsed DCs. As previously reported [37], TNBS also strongly
induced mRNA expression for IL-10, which could not be inhibited
by potent anti-inflammatory drugs. In the present study, we
observed a similar increase of IL-10 mRNA levels as well as TGFb
Figure 8. Result of the in vivo administration of anti-CD25 mAb (PC61)
on the protective effect of probiotic-pulsed BMDCs in TNBS-induced
colitis. Ten mice per group were challenged with TNBS alone (CTL) or
after Lr32-pulsed BMDC transfer (Lr32-DC). The effect of a pre-treatment
by either 200 mg of anti-CD25 (a-CD25) or control rat IgG (rat IgG) mAb,
24 h before colitis induction was analyzed in mice treated or not by
Lr32-pulsed BMDC (Lr32-DC) transfer. Wallace inflammation scores
(mean 6 SEM) were calculated in each group and compared to each
other by a Mann-Whitney U test (,0.01, **; p,0.001, ***). Percent of
mortality and protection (reduction of the mean Wallace scores of mice
treated with BMDCs, in relation to the mean score of TNBS control
group) are also reported.
doi:10.1371/journal.pone.0000313.g008
Figure 9. Protective effect of intra-peritoneal administration of
untreated (DC) or Lr32-treated BMDCs (Lr32-DC) derived from C57Bl/6
WT or MyD882/2, TLR22/2, NOD2 2/2 or IL-102/2 KO mice on TNBS-
induced colitis in C57Bl/6 mice. For technical reason, the protective
effect of all KO BMDC’s have not been analyzed in the same experiment.
For that reason, results are only expressed as the reduction (in %) of the
mean macroscopic inflammation scores of mice treated with BMDCs, in
relation to the mean scores of non-treated mice (corresponding control
TNBS). Significance values p,0.05 (*) or p,0.01 (**), as compared to the
corresponding TNBS-control group or the groups that received the
corresponding non-treated BMDCs, were calculated by the Mann-
Whitney U test (n = 10). The dashed line indicates the 25% threshold of
the uncertain statistical significance as previously described (48).
doi:10.1371/journal.pone.0000313.g009
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after TNBS administration which was prevented by Lr32-pulsed
DCs. Surprisingly, while the two protective strains used in this
study were previously shown to induce high IL-10 production in
human PBMCs (Table 1), we could not confirm this property
when using murine BMDCs. Nevertheless, in both in vitro models,
low production of pro-inflammatory mediators was an appropriate
indicator of strains harboring protective efficacy in colitis. IL-10-
dependent regulatory cells have been suggested to be involved in
the protective effects of probiotics. However, in IL-10 deficient
mice, which spontaneously develop colitis, probiotic administra-
tion could resolve inflammation, suggesting that their protective
effect could be IL-10 independent [7]. In our study, mice were
indeed protected by Lr32-pulsed BMDCs derived from IL-10
deficient mice, suggesting that the beneficial effect elicited by
conditioned DCs is also independent of IL-10.
Moreover, we could demonstrate that the protective effect of
probiotic-conditioned BMDCs was linked to the presence of
CD4+ CD25+ cells, since protection was not achieved in mice
depleted of CD25+ cells. Similarly, it has been shown that
immature DCs, whose NFkB-signaling pathway was blocked by
a proteosome inhibitor, could be a source of antigen-specific
regulatory cells that displayed in vitro and in vivo inhibitory effects in
an IL-10 independent manner [38]. The mechanisms, by which
these regulatory T cells are derived, remain to be defined.
Grohman [19] proposed that tolerogenic DCs could exert
regulatory effects on T cells by the expression of indoleamine 2,
3 dioxygenase (IDO), that lead by locally depleting tryptophan to
initiates an immunosuppressive pathway. The colonic over-
expression of IDO we observed, suggests that it could be one
mechanism by which probiotic-treated DCs could exert regulatory
effects. Interestingly, in the colon of protected mice we observed
a parallel enhancement of IFNc, which has been shown to be the
principal inducer of IDO expression.
The innate immune system is triggered by various pattern
recognition receptors (PRR), including TLR and NOD families.
PRR signaling must be properly regulated and multiple pathways
seem necessary to dampen or reduce the signaling, thereby
maintaining immune homeostasis. While deregulated interaction
between molecular pattern and TLRs may promote chronic
inflammation and tissue damage, recognition of commensal
bacteria by TLRs plays an important role in maintaining intestinal
homeostasis and contributes to the prevention of intestinal injury
[4]. To investigate the role of PRR signaling in the protective
effects of probiotic, Lr32-pulsed BMDCs derived from MyD88,
TLR2 and NOD2 deficient mice were transferred to TNBS-
treated mice. The administration of deficient BMDCs conditioned
by the probiotic strain, did not affect the course and severity of
colitis, indicating the involvement of both the TLR2 and NOD2
signaling pathways in the control of the colitis. Since the innate
immune system of the intestine has evolved in the presence of
luminal bacteria, it is reasonable to hypothesize that normal
intestinal function may be regulated by bacteria through TLRs.
CpG oligonucleotides have also been shown to prevent murine
colitis, supporting also the essential role of TLR9 signaling [39].
Genetic evidence supports a role of PRR in IBD, since
polymorphisms in NOD2 and to a lower extent in TLR9 genes
have been linked with Crohn’s disease [40,41]. Recently
Watanabe and colleagues proposed that peptidoglycan (PGN)-
mediated activation of TLR2 signaling is negatively regulated by
MDP-mediated activation of NOD2 signaling [42]. In the absence
of NOD2, the negative regulation in response to PGN is impaired,
leading notably to an enhanced IL-12 production both in vitro and
in vivo. The observed synergy between TLR9 and NOD2 is
apparently lacking in NOD2 homozygous CD patients, suggesting
implications for PRR-mediated intestinal homeostasis and in-
flammation [43]. Whatever the details of the mechanisms
involved, it is now apparent that the function of TLRs and NODs
could be combinatorial and might be synergistic or antagonistic
and that PRR signaling is likely to promote the induction of
regulatory cells to maintain tissue homeostasis.
We recently illustrated the importance of cell wall components
in the pro- versus anti-inflammatory properties of LAB [29]. As
suggested by Travasso et al [44], we could speculate that PGN
from tolerogenic probiotic could impact on the TLR2 signaling
cascade through NOD2 interaction. Nevertheless, we could not
exclude the potential role of DNA mediated by TLR9 signaling in
the effect of probiotics on DC function. These results raise the
critical question of how certain bacteria exert (or not) their anti-
inflammatory potential. To answer this question, purification of
bacterial components of different probiotic strains, able (or not) to
prime tolerogenic DCs is in progress. By analyzing both in vitro and
in vivo effects of such compounds, we hope to unravel exactly how
probiotics exert their immunoregulatory effects, and clarify the
role of PRR signaling.
Finally, perspectives for the use of probiotic-primed DCs are
manifold. Substantial reports describe immunosuppressive agents,
able to generate regulatory DCs that can be used to treat
transplant rejection and autoimmune diseases [45], but nothing
has been published so far for IBD. Despite increasing knowledge
about the immune-pathology of IBD, the therapeutic options are
still limited today. In this work we demonstrated that probiotics,
however, are able to induce tolerogenic DCs, offering a potential
therapy and providing important clues as to the mechanisms
underlying their anti-inflammatory properties. The selection of
suitable probiotic strains, bacterial components or the design of
potent cell wall mutants or recombinant strains to condition DCs
may become an attractive alternative for treating IBD or other
immunological disorders.
MATERIALS AND METHODS
Bacterial strains and growth conditions
Lactic acid bacteria used in this study are listed in Table 1.
Lactobacilli were grown at 37uC in MRS broth (Difco, Detroit,
Mich.), L. lactis strain was grown at 30uC in M17 supplemented
with 0.5% glucose and the E. coli TG1 strain was grown at 37uC in
Luria broth. For cell stimulation, bacteria were grown overnight,
harvested by centrifugation, washed twice in sterile PBS pH 7.2,
and resuspended at 109 CFU per ml in PBS containing 20%
glycerol. Suspensions were stored at 280uC until used for
stimulation assays. For direct intra-peritoneal administration to
mice, bacteria were grown overnight, washed twice and
resuspended at 108 CFU/ml in PBS.
Bone Marrow-Dendritic Cell (BMDC) generation
BMDCs were generated from the bone marrow precursors isolated
from femurs and tibias of mice as described by Lutz et al. [46], with
minor modifications. Bone marrow cells were prepared from wild-
type female BALB/c or C57BL/6 mice (Charles river, France) and
from TLR2 knock-out (KO) mice (TLR22/2) (obtained from S.
Akira [47] (Osaka University, Osaka, Japan), via a generous gift of
B. Ryffel (CNRS GEM2358, Orleans, France) and F. Trottein
(INSERM U567, Lille, France), MyD88 KO mice (MyD882/2)
[47], IL-10 KO (IL102/2) mice (Charles river, France). C57BL/6
background NOD2 KO mice were generated in the laboratory of
M. Giovannini (Barreau et al, in preparation). The first NOD2
coding exon carrying the majority of the sequence encoding the
CARD domains including the start codon, was deleted resulting in
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a null NOD2 allele. Germ line transmitting chimeras were crossed
to C57BL/6 mice to generate NOD2+/2 mice. After ten
backcrosses with C57BL/6 mice, NOD2+/2 mice were intercrossed
to generate NOD22/2 mice. NOD22/2 mice were indistinguish-
able from controls and showed no signs of liver pathology. All mice
were housed in specific pathogen free (SPF) conditions. The defect
in TLR2 and NOD2 in the respective KO mice was confirmed
using specific ligands, respectively Pam3Cys-Ser-(Lys)4 (PamC3, at
15 mg per ml, Calbiochem, Germany) and N-Acethylmuramyl-L-
alanyl-D-iso-glutamine hydrate (MDP, at 100 mg per ml, Sigma,
ST-Louis, MI, USA) while LPS (at 100 ng per ml, Sigma) was
used as positive control (data not shown). Briefly, after red cell
lysis, BM cells were cultured at 26105 cells/ml using Petri dishes
and Iscove medium (Sigma-Aldrich, St. Louis, MO) supplemented
with 10% heat-inactivated fetal calf serum (FCS, Gibco-BRL,
Paisley, Scotland), 50 mM 2-mercaptoethanol, 1 mM glutamine,
50 mg/ml gentamycin and 10% of supernatant from a granulocyte-
macrophage colony-stimulating factor-expressing cell line (GM-
CSF transfected J588 myeloma cell line). Freshly prepared
medium was added every three days and BMDCs were used on
day 11 of culture (maximum of CD11c expression as checked by
FACS analysis).
BMDC stimulation
BMDCs (56105 cells/ml) were stimulated with 56106 bacteria/ml
in the presence of 150 mg/ml gentamycin or were left untreated.
After 18–20 h, culture supernatants were collected, clarified by
centrifugation and stored at 220uC for cytokine and chemokine
analysis. For in vivo cell transfer, BMDCs were washed 3 times in
PBS and resuspended at 26106 cells in 200 ml. No remaining
viable bacteria were detected in the cell suspensions, as checked by
plating on MRS medium. Conditioned medium was obtained by
using the supernatant after filtration using a 0.22 mM MilliporeTM
membrane (Bedford, MA).
Electron microscopy
LAB-pulsed BMDC were processed for electron microscopy
according to Noe¨l et al [48], slightly modified. Briefly, after the
primary fixation, cells were washed 3 times in 0.1 M sodium
cacodylate buffer pH 7. 4, pellets were encapsulated in 2%
solution of low melting point agarose, before proceeding to post-
fixation, dehydration and embedding. Ultrathin sections were
stained with uranyl acetate, lead citrate and examined under
a Hitachi 7500 electron microscope.
Immunocytostaining and flow cytometry
For FACS analysis (expression of surface markers), cells were
collected by gentle pipetting, centrifuged for 10 min at 3006 g,
and resuspended in cold PBS containing 1% (v/v) FCS, and 0.1%
sodium azide (PBS-FCS-Az). For all staining, cells were incubated
with Fc receptor-blocking mAb anti-CD32 (2.4G2). The following
Abs used for staining were purchased from BD Pharmingen:
FITC-conjugated anti-mouse CD11c (HL3); PE-conjugated anti-
mouse MHC II (I-A/I-E; M5); PE-conjugated anti-mouse CD86
(GL1); PE-conjugated anti-mouse CD80 (16-10A1); PE-conjugat-
ed anti-mouse CD40 (3/23) and appropriate mAb isotypic
controls and from eBioscience: FITC-conjugated anti-CD4
(RM4-5) and PE-conjugated anti-CD25 (PC61.5). Cells were
incubated with selected mAb for 30 min on ice and at low light
exposure. Thereafter, cells were washed with 3 ml PBS-FBS-Az
and finally resuspended in 300 ml paraformaldehyde 1% for flow
cytometric analysis using a FACS-Calibur flow cytometer and
CellQuest software (BD Biosciences, San Jose, CA).
Cytokine and chemokine quantification in culture
supernatants
Murine IL-12(p70), IL-10, IL-6 and TNF-a were analyzed using
matched Ab pairs purchased from BD Pharmingen (BD
Biosciences, San Jose, CA). MIP-1a and MIP-2 were similarly
analyzed using commercially available ELISA kits (R&D systems,
Minneapolis, MN) according to the manufacturer’s instructions.
Induction of colitis
Animal experiments were performed in an accredited establish-
ment (number A59107; animal facility of the Institut Pasteur de
Lille, France) and carried out in accordance with the guidelines of
laboratory animal care published by the French Ethical Commit-
tee and the rules of the European Union Normatives (number 86/
609/EEC). BALB/c and C57Bl/6 (female, 8 weeks) were
obtained from Charles River (St Germain sur l’Arbresle, France).
A standardized murine TNBS colitis model was used to induce
acute levels of inflammation [49]. Briefly, anesthetized mice
received an intra-rectal administration of 50 ml solution of 2,4,6-
trinitrobenzene sulfonic acid (TNBS, Sigma-Aldrich Chemical,
France) (100 mg/kg for BALB/c mice and 150 mg/kg for C57Bl6
mice) dissolved in 0.9% NaCl/ethanol (50/50 v/v). Colons were
removed at sacrifice, 48–72 h after administration, washed and
opened. Inflammation grading was performed blindly using the
Wallace scoring method [50], reflecting both the intensity of
inflammation and the extent of the lesions. The protective effect of
untreated or LAB-pulsed DCs was studied by intra-peritoneal
administration of 26106 cells, 2 h before TNBS-colitis induction.
The same protocol was performed using 108 CFU live bacteria,
administered intra-peritoneally before colitis induction. A com-
mercial preparation of prednisone (Cortancyl, Sanofi Aventis,
France) was used as positive control of protection and was orally
administered for 3 subsequent days at 10 mg/kg starting at the
day of TNBS administration. Histological analysis was performed
on May-Gru¨nwald-Giemsa stained 5 mm tissue sections from colon
samples fixed in 10% formalin and embedded in paraffin. The
myeloperoxidase (MPO) activity was determined in distal colon
tissue by specific kinetic assays according to Bradley et al [51].
Immediately after sacrifice, colonic samples were taken and snap-
frozen on liquid nitrogen after which they were stored at 280uC.
Pure MPO from human neutrophils (Sigma-Aldrich Chemical,
France) was used as a standard. One unit of MPO activity was
defined as the quantity of MPO degrading 1 mmol hydrogen
peroxide/min/ml at 25uC. Data are expressed as international
unit (IU) of MPO per cm of colon tissue. Serum amyloid A (SAA)
protein were measured by ELISA using commercial kits from
Biosource International (Camarillo, Ca, USA) according to the
manufacturer recommendations.
For RT-PCR analysis, a part of the colon corresponding to the
enflamed region was cleaned from fecal material and stored in
RNA-laterR buffer (Ambion, Austin, TX, USA) at 280uC until
RNA extraction.
In vivo depletion of CD4+ CD25+ population
In order to analyze the impact of the CD4+ CD25+ Treg cell
population, CD25+ cells were depleted by intra-peritoneal
injection of 200 mg per BALB/c mice of purified rat IgG
monoclonal antibody (mAb) anti-CD25 produced by hybridoma
PC61 [52], in comparison with an isotypic control (mAb ATCC
HB 152), 24 h before BMDCs administration and TNBS-colitis
induction. Depletion was checked by flow cytometry using anti
FITC-labeled anti-CD4 and PE-labeled anti-CD25 mAbs.
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Quantitative real time RT-PCR
Total RNA from individual colons was purified by using
NucleoSpin RNA II kit (Macherey-Nagel, Du¨ren, Germany),
including a DNase treatment according to the manufacturer’s
recommendations. Reverse transcription of total RNA (2 mg) was
performed with random primers (Amersham, Piscataway, NJ,
USA) and Superscript II (Invitrogen, Carlsbad, CA, USA). Fifty
nanograms of template were used in a real-time PCR reaction
with a final volume of 25 ml using the Taq-Man PCR Master Mix
(Applied Biosystems, Branchburg, NJ, USA), and the primers and
probes designed by Applied-Biosystems (Assays-on-demand) for
murine TNF-a (Mn00443258), IL-6 (Mm00446190), IL-1b
(Mm00434228), IL-12 (Mm00434170), IL-23 (Mn00518984), IL-
17 (Mm00439619), Cox-2/Ptgs2 (Mn00478374), MIP-2/CxCl2
(Mn00436450), IFNc (Mm00801778), IL-10 (Mn00439616), IFNb
(Mm00439546), TGFb (Mm004441724), IDO (Mm00492586)
and b-actin (Mn00607939), as suggested by the manufacturer. All
reactions were performed in duplicate, and the thermal cycling
conditions were 10 min at 95uC, followed by 40 cycles of 15 s at
95uC and 1 min at 60uC using the Applied Biosystems 7300 real
time PCR system. For relative quantification, we compared the
amount of target normalized to the b-actin amplification by using
the 2 2DDCt formula representing the n-fold differential expression
of the target gene in the treated sample, compared with sample
from naı¨ve mice (control), where Ct is the mean of threshold cycle,
DCt was the difference in the Ct values for the target gene and the
b-actin reference gene (for each sample), and DDCt represents the
difference between the Ct from the control and each sample. Non-
template (NTC) and Reverse-transcription (RTC) control were
included for each quantification experiment.
Statistical analysis
Comparisons between the different animal groups were analyzed
by the non-parametric one–way analysis of variance, Mann-
Whitney U test. Differences were considered to be statistically
significant when the p value was ,0.05. For in vivo experiments,
only protection levels exceeding the 25% level (positive and
negative) were considered to be relevant, as previously shown [48].
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